https://retina.news.mail.ru/prev780x440/pic/d1/40/main41785519_fb54686701597d577113d79d66bcec0b.jpg

“news” figured out how to pass free testing in Moscow and cost alternative studies.

In Moscow launched an unprecedented research program herd immunity with antibody tests for SARS-CoV-2. To do this in 30 clinics in the capital opened two treatment rooms. To pass the test from the end of this week will be able to residents across the country. The market of domestic tests which are much cheaper than foreign ones, their value will start at 950 rubles. “News” analyzed the Russian market of screening systems and compared the potential of different tests. According to interviewed by “Izvestia” experts, the launch mass diagnosis will allow more details to track the dynamics of the epidemic and the time to cancel the restrictive measures.

Scientists and the Moscow authorities initiated science-based population-based screening to be conducted in 30 adult polyclinics of the city. Each of them will be two treatment rooms, which will install a free blood analyzers.

Scheduled daily testing of about 70 thousand inhabitants — they will receive an invitation for a free testing, once recorded on the procedure online.

Passing IFA-testing (ELISA — enzyme-linked immunosorbent assay used to detect the presence or absence in the blood of the patient IgM antibodies (a marker for the presence of coronavirus infection) and IgG (a marker of immunity to coronavirus infection), the city will receive information about their immune status.

According to mayor Sergei Sobyanin, by the end of may the total capacity of the urban system IFA-test exceeds 200 thousand analyses per day. The measures described will allow you to know exactly what the real dynamics of the spread of infection — which will enable the authorities to understand when to take quarantine measures.

up To this point Russia has only one functioning domestic system for the detection of antibodies to SARS-CoV-2. 10 APR Creator tests — State scientific center “Vector” has registered in Roszdravnadzor, having passed all the necessary technical and clinical tests. However, these tests were only used for analyses of health workers. Ordinary citizens were not available.

April 30, on receipt of registration reported FMBA, and may 1 — SMRC Hematology, Ministry of health. However, according to “Izvestia”, these tests on the market has not yet been received.

About the imminent start of mass use of tests and declared the company “Invitro”. Necessary registration certificate will be received in a few days.

Received in our offices of biological material will quickly send in five major laboratoryiy, which will host research, — said the Director of public relations of the company Nina Oreshkina. —.

Some research group have created these tests, the company said. The specific cost of the study will depend on the system used (combination of reagents and technology, which is used in this case), and the type of the test — it is quantitative research or qualitative. In addition, the price directly depends on the decision of the manufacturer tests.

the company Also said that they plan to introduce tests for the presence of antibodies and their concentration in the blood of the patient. This option will provide an opportunity to learn not only about the fact transferred COVID-19, but also to assess the severity of the immune response to the disease.

As practice shows, these two options have different market price.

in the “Invitro” is decided to stay only on the detection of IgG antibodies, whose presence in the blood suggests that he’s already had COVID-19 and after infection was more than two weeks.

— If you talk about the antibodies of type IgM, they signal the development of the acute stage of the disease when the office visit for testing is impractical because of high risks to staff and other clients, said the company.

Antibodies are special proteins produced by the body in response to infection. This feature makes them a good indicator for medical diagnosis. The first matter that appears in the blood after the threat of immunoglobulin IgM, signaling the beginning of the disease. After a few days, join antibodies of the IgG class, which provides the primary immune response. In parallel with these two agents against infection acts substance IgA, which blocks the penetration of pathogens through mucous membranes. Also to fight infections, the body uses white blood cells and T-lymphocytes activity which can be assessed using the ELISPOT test.

In early June, the market will be another test for antibodies, which was created by the Centre for genetics and reproductive medicine Genetico.

In its development, we used the antigen (the section of the virus SARS-CoV-2), which is associated with its unique S-protein, in the thorns “crown” of the virus. Encryption technology this component was passed to us by colleagues from the American medical at Mount Sinai, said the center’s Director, Artur Isaev. As a result, we have created a test system with high specificity, reaching 98-100%. It will allow not to confuse antibodies to SARS-CoV-2 with antibodies produced after exposure to other coronaviruses.

soon the Russian market will be a test, conver��culated by the company “Hema”. Her product was already licensed, however, the representatives of the organization are unable to provide “news” online comment.

— Get the result of the presence of IgG antibodies to the coronavirus can be a real relief for a person because it suggests that he previously had mild or asymptomatic form, as well as a significant reduction in the risk of infection in the future, — says researcher of the chemical and biological departments of Moscow state University. M. V. Lomonosov Teymur Aliyev.

the Russian tests for antibodies to the coronavirus not yet available for the consumer — instead, the clinics use foreign manufacturers which have already received the appropriate permissions. It happened due that they have international certificates, simplifying the licensing procedure.

This information was confirmed by a survey that “news” was carried out among private medical organizations. In particular, the clinic of academician Roitberg system is applied Biozek medical (Netherlands), Global Medical System uses the South Korean development Sugentech and clinics Chaika Health and “Dawn” have made their choice in favor of Chinese product INNOVITA.

According to employees of the mentioned institutions, to analyse the patient should come to them for the sampling of biological material, after which the results will be sent via email within a few hours. The study costs depending on the type of test ranges from 3 thousand to 7 thousand rubles. The waiting list for services is not observed — in most cases, to arrange visits to the clinic either the same day or the next.

— Tests that currently use in private clinics, show very different results in quality, — said the co-founder of the clinic “Dawn” Evgeny Boychenko. Therefore, when selecting a system you need to look carefully at the results of her laboratory test formal (they are for obtaining a license), and secondary.

Testing for antibodies is useful in General for the country, as it allows to understand the extent of the epidemic in the country, says associate Professor of the Department of Biophysics at MIPT Oleg Batishchev.

— the Mass testing allows you to determine how many people actually had SARS-Cov-2, including asymptomatic, but also how stable they develop immunity. — the expert believes. — Efficiency tests — is another question. Obviously, they must pass the necessary control on the interaction with other coronaviruses and can be used only those of them which showed the specificity of it with a new infection.

Start mass testing for antibodies to the coronavirus will also allow�� to assess the level of collective immunity to the disease, the citizens of Russia. He may be one of the most important indicators that will allow the state to more closely monitor the dynamics of the epidemic and the time to cancel the restrictive measures.

In the healthcare organization, registered tests at the time of publication had not responded to the request of “Izvestia”.